Gossamer Bio (GOSS) Capital Expenditures (2018 - 2025)

Gossamer Bio (GOSS) posted quarterly Capital Expenditures of $53000.0 for Q2 2025, up 103.85% quarter-over-quarter from $26000.0 in Q1 2025.

Gossamer Bio (GOSS) Capital Expenditures (2018 - 2025) Analysis & Trends

Gossamer Bio's Capital Expenditures history runs 6 years deep, the most recent figure standing at $53000.0 for Q2 2025.

In Q2 2025, Capital Expenditures changed N/A year-over-year to $53000.0; the TTM figure through Mar 2026 stood at $53000.0 (up 103.85% YoY), while the FY2025 annual figure was $79000.0, changed N/A from the prior year.
Capital Expenditures for Q2 2025 stood at $53000.0, up from $26000.0 in the prior quarter.
The five-year high for Capital Expenditures was $802000.0 in Q1 2021, with the low at -$940000.0 in Q3 2021.
The 3-year median for Capital Expenditures is $53000.0 (2025), against an average of $18000.0.
Peak annual rise in Capital Expenditures reached 130.26% in 2021, while the deepest fall reached 178.6% in 2021.
Gossamer Bio's Capital Expenditures stood at -$940000.0 in 2021, then surged by 76.06% to -$225000.0 in 2022, then soared by 123.56% to $53000.0 in 2025.
Business Quant data shows GOSS's Capital Expenditures at $53000.0 in Q2 2025, $26000.0 in Q1 2025, and -$225000.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	34.68 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	6.26 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	251.02 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-73.57 Mn
10	Gossamer Bio	50.34 Mn	-6.69 Mn	-	-

Download Data